Matthias an der Heiden
Biographic Data
| ID | 7446657 |
|---|---|
| NAME | Matthias an der Heiden |
| GIVEN NAMES | Matthias an der |
| FAMILY NAME | Heiden |
| SIGNATURE | HEIDEN M A D |
| AFFILIATIONS | Robert Koch Institute |
| ORCID | 0000-0001-5863-4549 |
| VERIFIED | Yes |
| TOTAL WORKS | 8 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 8 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2010 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Estimated number of people infected with hepatitis B and C virus in Germany in 2013
Introduction: Hepatitis B (HBV) and hepatitis C (HCV) viral infections are uncommon in Germany, though these infections have a higher prevalence among certain subpopulations, such as some first-generation migrant groups, people who inject drugs (PWID), and HIV-positive men who have sex with men (HIV+MSM). Repeated estimates of the number of people infected with HBV and HCV are essential to facilitate the monitoring and elimination efforts by 2030…
Changing socioeconomic inequalities in the incidence and case fatality rates of Covid-19 in Germany, March 2020 through May 2022
The association between socioeconomic position and COVID-19 impact in Germany has been complex, with patterns changing in intensity and direction over time. Continued monitoring of socioeconomic inequalities in COVID-19 impact, in particular at the individual level, is needed to better understand if and how inequalities continue to persist. Such monitoring will be instrumental in informing more equitable control strategies
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the treatment costs within the statutory health insurance (SHI) in Germany and per patient per month. Methods: Data on pharmacy bills of NUCs to patients with…
Estimates of global seasonal influenza-associated respiratory mortality
Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany
Determinants of HIV, viral hepatitis and STI prevention needs among African migrants in Germany; a cross-sectional survey on knowledge, attitudes, behaviors and practices
Study participants demonstrated good knowledge on HIV-transmission but knowledge gaps regarding HIV/STI-testing services, HEP and STI. This calls for targeted interventions providing more information about these topics in African communities in Hamburg and possibly also elsewhere
From pills to patients
A substantial increase in the number of people receiving ART was observed from 2006 to 2013 in Germany
Characteristics and risk factors for symptomatic Giardia lamblia infections in Germany
A substantial proportion of Giardia lamblia cases in Germany are indigenously acquired. Symptomatic cases are significantly more likely to be immunocompromised than control persons from the general population. Physicians should consider Giardia infections among patients with no recent history of travel abroad, particularly if they have immune deficiencies. Green salads may be an important vehicle of infection. Information campaigns highlighting t…
No prominent works on this page.
Characteristics and risk factors for symptomatic Giardia lamblia infections in Germany
A substantial proportion of Giardia lamblia cases in Germany are indigenously acquired. Symptomatic cases are significantly more likely to be immunocompromised than control persons from the general population. Physicians should consider Giardia infections among patients with no recent history of travel abroad, particularly if they have immune deficiencies. Green salads may be an important vehicle of infection. Information campaigns highlighting t…
Determinants of HIV, viral hepatitis and STI prevention needs among African migrants in Germany; a cross-sectional survey on knowledge, attitudes, behaviors and practices
Study participants demonstrated good knowledge on HIV-transmission but knowledge gaps regarding HIV/STI-testing services, HEP and STI. This calls for targeted interventions providing more information about these topics in African communities in Hamburg and possibly also elsewhere
From pills to patients
A substantial increase in the number of people receiving ART was observed from 2006 to 2013 in Germany
Estimates of global seasonal influenza-associated respiratory mortality
Risk behaviours and viral infections among drug injecting migrants from the former Soviet Union in Germany
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
Background: Germany is a low prevalence country for hepatitis B virus (HBV) infection with higher prevalence in vulnerable groups. The number of treated chronic hepatitis B (CHB) patients is unknown. We aimed to determine the number of CHB patients treated with nucleos(t)ide analogs (NUCs), the treatment costs within the statutory health insurance (SHI) in Germany and per patient per month. Methods: Data on pharmacy bills of NUCs to patients with…
Estimated number of people infected with hepatitis B and C virus in Germany in 2013
Introduction: Hepatitis B (HBV) and hepatitis C (HCV) viral infections are uncommon in Germany, though these infections have a higher prevalence among certain subpopulations, such as some first-generation migrant groups, people who inject drugs (PWID), and HIV-positive men who have sex with men (HIV+MSM). Repeated estimates of the number of people infected with HBV and HCV are essential to facilitate the monitoring and elimination efforts by 2030…
Changing socioeconomic inequalities in the incidence and case fatality rates of Covid-19 in Germany, March 2020 through May 2022
The association between socioeconomic position and COVID-19 impact in Germany has been complex, with patterns changing in intensity and direction over time. Continued monitoring of socioeconomic inequalities in COVID-19 impact, in particular at the individual level, is needed to better understand if and how inequalities continue to persist. Such monitoring will be instrumental in informing more equitable control strategies
Medicine (7 works) · Demography (4 works) · Environmental health (4 works) · HIV/AIDS Research and Interventions (4 works) · Internal Medicine (4 works) · Public health (4 works) · Biostatistics (3 works) · Demography (3 works) · Epidemiology (3 works) · Family medicine (3 works)